Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C

Inclusion Criteria: Subjects must a history of chronic HCV infection defined as documented HCV genotype 1 infection for at least 6 months. * Subjects must have: 1. Documented failure to respond to prior treatment or relapse with a combination of peg-interferon (peg-IFN), ribavirin (RBV), and either boceprevir or telaprevir, OR a combination of peg-IFN and ribavirin or 2. Subject is ineligible or unwilling to receive a combination of peg-IFN, RBV, and either boceprevir or telaprevir. * Female subjects have to be of non-childbearing potential, defined as meeting any of the following criteria: 1. Female subjects over the age 60. 2. Female subjects aged 45-60 years old must be amenorrhoeic for at least 2 years and must have serum follicle stimulating hormone (FSH) levels \> 30 IU/L. 3. Female subjects with hysterectomy or bilateral oophorectomy. All female subjects must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline. * Male subjects and their partners must be willing to comply with the following requirements to use 2 methods of effective contraception: Male subjects with a vasectomy must use a condom. Without a vasectomy, male subjects must use a condom. The female must be sterile or willing to use an additional form of contraception. * Baseline HCV RNA level of \> 100,000 IU/mL and: * No evidence of cirrhosis at Screening * At least 3 months since prior therapy for HCV * A willingness to enroll in a 5 year follow-up safety study Exclusion Criteria: * Body mass index \< 18.5 or \> 30 * Total body weight \> 80 KG * Female subjects of childbearing potential (including females with tubal ligation) or women who are pregnant or nursing * Male subjects who are unwilling to provide the required semen samples * Presence of nAb levels to AAV8 that abrogate AAV8 transduction * Severe Liver disease * Hepatocellular carcinoma (HCC) or suspicion of HCC * Coronary artery disease * Platelet count of \< 150 x 109/L or Creatinine ≥ 1.5 mg/dL at Screening * Hypertension with systolic blood pressure consistently ≥ 130 mmHg or diastolic blood pressure consistently ≥ 90 mmHg * Screening examinations indicative of possible occult malignancy unless cancer has been excluded * Family history of colon cancer in any first-degree relative unless ruled out by colonoscopy * Positive for human immunodeficiency virus 1 (HIV1) or HIV2 antibody * Co-infection with hepatitis B virus * History of autoimmune disease * Renal impairment * Hospitalization for liver disease within 60 days of Screening * Use of drugs of abuse in the prior 3 months * Other concomitant disease or condition likely to significantly decrease life expectancy or cancer * Treatment with an investigational drug within 6 months preceding the first dose of trial medication * Received an AAV vector previously or any other gene transfer agent in the previous 6 months * History of cardiac abnormalities, as assessed at the Screening Visit * Twelve-lead ECG demonstrating QTcB \> 465 ms at Screening * Chronic hepatic diseases * Evidence of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, psychiatric, neurologic, or allergic diseases. * Evidence of autoimmune disease or pre-existing autoimmune or antibody-mediated diseases * Use of immunosuppressive medications within 6 months before the entry into this study, except for inhaled or topical corticosteroids